Journals / İzmir Tepecik Eğitim Hastanesi Dergisi / 2008 / Cilt: 18 - Sayı: 1

The effecteveness of valproat and oxcarbazepine monotherapies in children with benign rolandic epilepsy

Benin rolandik epilepsili çocuklarda tekli valproat ve okskarbazepin tedavilerinin etkinliği

Pages
20–24
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSION: The findings from this small series suggest that valproat or oxcarbazepine monotherapies can be effective and well tolerated in childhood.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: In childhood, benign rolandic epilepsy is one of the most seen partial seizures with good prognosis.
📊
Key Findings & Data:METHODS: A retrospective chart review identified 32 patients (mean age: 8.06 ± 2.89 years; range: 4-14 years; 56.3% male; VPA group: 16 cases; OXC group: 16 cases) with benign rolandic epilepsy receiving valproat or oxcarbazepine monotherapy in at least one year.
💡
Conclusion & Impact:CONCLUSION: The findings from this small series suggest that valproat or oxcarbazepine monotherapies can be effective and well tolerated in childhood.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

AIM: In childhood, benign rolandic epilepsy is one of the most seen partial seizures with good prognosis. The comparative studies which analyse the effectiveness of oxcarbazepine (OXC) in benign rolandic epilepsies were rarely. In this study, the clinical and adverse effects of sodium valproat (VPA) and OXC were compared. METHODS: A retrospective chart review identified 32 patients (mean age: 8.06 ± 2.89 years; range: 4-14 years; 56.3% male; VPA group: 16 cases; OXC group: 16 cases) with benign rolandic epilepsy receiving valproat or oxcarbazepine monotherapy in at least one year. In statistical analysis, Mann-Whitney U and chi-square tests were used and p<0.05 was considered as significant. RESULTS: In each therapy groups, 10 patients (67.5%) achieved seizure-free state (p>0.05). At the end of the first three months after the beginning of antiepileptic therapy, one patient in valproat group and two patients in oxcarbazepine group had insufficient reduction in seizure frequency, so they were switched to another antiepileptic agent. Three patients [18.7% (hyperphagia in 2, abdominal pain in 1)] in valproate group and 6 patients [37.5% (drowsiness in 3, headache in 2, skin rash in 1) in oxcarbazepine group reported adverse events (p>0.05). CONCLUSION: The findings from this small series suggest that valproat or oxcarbazepine monotherapies can be effective and well tolerated in childhood.

Özet

AMAÇ: Çocukluk çağında benin rolandik epilepsi sık görülen ve prognozu iyi olan bir parsiyel epilepsi tipidir Benin rolandik epilepsi tedavisinde okskarbazepin (OKS) etkinliğini değerlendiren karşılaştırmalı çalışmaların sayısı sınırlıdır. Bu çalışmada, tek başına sodyum valproat (VPA) ve OKSC tedavisi alan benin rolandik epilepsili olgularda antiepileptik ilaç etkinliği ve yan etki profilleri karşılaştırılmışttr. YÖNTEM: Benin rolandik epilepsi tanısı alan, tek başına VPA veya OKS tedavisi ile en az 1 yıl izlenen toplam 32 olgu (ortalama yaş: 8.06 ± 2.89 yıl; yaş dağılımı: 4-14 yıl, % 56.3'ü erkek; VPA grubu: 16 olgu; OKS grubu: 16 olgu) geriye dönük incelenmiştir. İstatistiksel değerlendirmede Mann-Whitney U ve ki-kare testleri kullanılmış olup p 0.05). Tedavi sonrası ilk 3 aylık dönemin sonunda VPA grubunda 1 olguda, OKS grubunda 2 olguda yeterli nöbet kontrolü sağlanamadığından almakta oldukları antiepileptik tedaviler değiştirilmiştir. VPA grubunda 3 olguda [%18.7 (2'sinde iştah artışı, l'inde karın ağrısı)], OKS grubunda ise 6 olguda [%37.5 (3'ünde uykuya eğilim, 2'sinde baş ağrısı ve l'inde cilt döküntüsü)] antiepileptik ilaca bağlı semptomatik yan etki saptanmıştır (p>0.05). SONUÇ: Sınırlı sayıda olguyu içeren bu çalışma, çocukluk çağında benin rolandik epilepsinin tek ilaçla tedavisinde valproat ve okskafbazepinin, etkili ve kolay kullanılabilen antiepileptik ilaçlar olduğunu desteklemektedir.

🔖

Cite This Article

ANIL, M., DİZDARER, G., BAL, A., UZUN, O., AKSU, N. (2008). The effecteveness of valproat and oxcarbazepine monotherapies in children with benign rolandic epilepsy. İzmir Tepecik Eğitim Hastanesi Dergisi, Cilt: 18 - Sayı: 1, 20–24. https://ajindex.com/articles/268591

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Serdaroğlu G, Tekgül H. Çocukluk ve ergenlik dönemi idiyopatik epilepsileri, in: Aysun S, Anlar B, Altunbaşak Ş, Deda G, Serdaroğlu A, editörler. Çocuk Nörolojisi. Ankara: Alp Ofset; 2006: 351-72
  2. Johnston MV. Seizures in childhood. In: Kliegman RM, Behrman RE, Jenson HB, Stanton BF, editors. Textbook of Pediatrics. 18th ed. Philadelphia: WB. Saunders, 2007: 2457-75
  3. Sztajnkrycer MD. Valproic acid toxicity: overview and management. Glin Toxicol 2002; 40: 789-801
  4. Serdaroğlu G, Kurul S, Tutuncuoglu S, Dirik E, Sarioglu B. Oxcarbazepine in the treatment of childhood epilepsy. Pediatr Neural 2003; 28: 37-41
  5. De Silva M, MacArdle B. Randomized comparative monotherapy trial of phenobarbital, phenitoin, carbamazepine or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996; 16: 709-13
  6. Wheless JW, Glarke DF, Arzimanoglou A, Carpenter D. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disord 2007; 9: 353-412
  7. Ambrosio AF, Soares-Da-Silva P, Carvalho CM, Carvalho AP. Mechanisms of action of carbamazepine and its derivates, oxcarbazepine, B1A 2-093, and B1A 2-024. Neurochem Res 2002; 27: 121-30
  8. Kothare SV, Khurana DS, Mostofı N, et al. Oxcarbazepine monotheraphy in children and adolescents: a single-center clinical experience. Pediatr Neural 2006; 35: 235-39
  9. Wellington K, Goa KL. Oxcarbazepine: an update of efficacy in the management of epilepsy. CNS Drugs 2001; 15: 137-63
  10. Dam M, Ekberg R, Loynig Y, Waltimo O, Jakobsen K. A double blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed previously untreated epilepsy. Epilepsy Res 1989; 3: 70-6
  11. McKee PJ, Blacklaw J, Forrest G, et al. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. Br J Clin Pharmacol 1994; 37: 27-32
  12. Clemens B, Menes A, Piros P, et al. Quantitative EEG effects of carbamazepine, oxcarbazepine, valproate, lamotrigine, and possible clinical relevance of the findings. Epilepsy Res 2006; 70: 190-9
  13. Christe W, Kramer G, Vigonius U, et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997; 26451-60
  14. Kothare SV, Mostofı N, Khurana DS, et al. Oxcarbazepine therapy in very young children: a single-center clinical experience. Pediatr Neural 2006; 35: 173-76
  15. Franzoni E, Garone C, Sarajlija J, et al. O